Intra-Cellular Therapies Inc. (ITCI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Intra-Cellular Therapies Inc. (ITCI)
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Key Insights
Critical company metrics and information
Share Price
$84.55Market Cap
$8.96 BillionTotal Outstanding Shares
106.02 Million SharesTotal Employees
561Dividend
No dividendIPO Date
December 19, 2013SIC Description
Pharmaceutical PreparationsHomepage
https://www.intracellulartherapies.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-137.84 Million |
Net Cash Flow From Financing Activities, Continuing | $564.91 Million |
Net Cash Flow From Financing Activities | $564.91 Million |
Net Cash Flow From Operating Activities | $-62.16 Million |
Net Cash Flow From Investing Activities, Continuing | $-137.84 Million |
Net Cash Flow From Operating Activities, Continuing | $-62.16 Million |
Net Cash Flow | $364.91 Million |
Net Cash Flow, Continuing | $364.91 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Revenues | $613.73 Million |
Income Tax Expense/Benefit | $1.24 Million |
Income/Loss From Continuing Operations Before Tax | $75.10 Million |
Income/Loss From Continuing Operations After Tax | $-86.37 Million |
Basic Earnings Per Share | $0.87 |
Research and Development | $216.61 Million |
Diluted Earnings Per Share | $0.87 |
Operating Income/Loss | $-121.62 Million |
Costs And Expenses | $704.83 Million |
Diluted Average Shares | $102.27 Million |
Basic Average Shares | $102.27 Million |
Benefits Costs and Expenses | $538.63 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-86.37 Million |
Operating Expenses | $735.35 Million |
Other Operating Expenses | $518.74 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Parent | $-86.37 Million |
Net Income/Loss | $-86.37 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Parent | $1.14 Billion |
Noncurrent Assets | $52.71 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $179.62 Million |
Noncurrent Liabilities | $13.51 Million |
Current Liabilities | $166.11 Million |
Other Non-current Assets | $50.71 Million |
Accounts Payable | $10.34 Million |
Assets | $1.32 Billion |
Inventory | $23.54 Million |
Liabilities And Equity | $1.32 Billion |
Fixed Assets | $2.00 Million |
Current Assets | $1.27 Billion |
Other Current Assets | $1.25 Billion |
Other Current Liabilities | $155.78 Million |
Equity | $1.14 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.